5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street

Motley Fool2021-06-08

If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

285

Report

Comment（217）

Shan_2021
·2021-06-17
Not sure time will tell
Reply
Like
Report
zactan
·2021-06-15
Okay
Reply
Like
Report
Jac_jk
·2021-06-10
Plug power financial report better be good
Reply
1
Report
Fold Replies
- 王尧SICS5:
  Yep!
  2021-06-11
  Reply
  Report
- Jac_jk:
  Oh dear, another delayed ?
  2021-06-11
  Reply
  Report
- 王尧SICS5:
  It defered 3 times!
  2021-06-11
  Reply
  Report
Monching
·2021-06-09
Okay
Reply
Like
Report
WCS1981
·2021-06-09
Missed buying teladoc at $130[LOL]
Reply
2
Report
iamateh
·2021-06-09
pls like and comment. thanks!!
Reply
1
Report
A68
·2021-06-09
[Happy]
Reply
4
Report
HappyCloud
·2021-06-09
Pls like and comment. Thanks
Reply
2
Report
MengKeng
·2021-06-09
Vaxart is interesting as it is developing a pill instead of injection for Covid-19. Hope it can be released so that shares will rise
Reply
4
Report
Fold Replies
- vxfReplying toBonghanhuei:
  respond
  2021-06-10
  Reply
  Report
- vxfReplying toJeffTai:
  thanks
  2021-06-10
  Reply
  Report
- JeffTaiReplying toBonghanhuei:
  good
  2021-06-09
  Reply
  Report
View more 2 comments
jun26
·2021-06-09
Like comment
Reply
6
Report
Fold Replies
- Kelvinphan:
  Done... pls help response back
  2021-06-09
  Reply
  Report
- Kelvinphan:
  Thanks
  2021-06-09
  Reply
  Report
- vxf:
  respond back
  2021-06-09
  Reply
  Report
View more 2 comments
LHJarsenal
·2021-06-09
Like n comment pls
Reply
4
Report
Fold Replies
- vxf:
  respond
  2021-06-09
  Reply
  Report
mreddeham
·2021-06-09
Comment pls
Reply
3
Report
Fold Replies
- vxf:
  raspberry up please
  2021-06-09
  Reply
  Report
Jamessss
·2021-06-09
Like and comment
Reply
6
Report
Fold Replies
- Permapurps:
  Like and comment please
  2021-06-09
  Reply
  Report
- vxf:
  respond please
  2021-06-09
  Reply
  Report
zhenx
·2021-06-09
Wow
Reply
5
Report
Fold Replies
- vxf:
  respond please
  2021-06-09
  Reply
  Report
- zhenx:
  ok
  2021-06-09
  Reply
  Report
- vxfReplying tozhenx:
  thank
  2021-06-09
  Reply
  Report
View more 2 comments
Kayabunz
·2021-06-09
Like likeeeee
Reply
7
Report
Fold Replies
- GiselleC:
  Ok
  2021-06-09
  Reply
  Report
GiselleC
·2021-06-09
Pls like n comment
Reply
4
Report
Fold Replies
- zhenx:
  done
  2021-06-09
  Reply
  Report
Kelvinphan
·2021-06-09
Like & comment
Reply
5
Report
Fold Replies
- Kelvinphan:
  Thanks
  2021-06-09
  Reply
  Report
- Kelvinphan:
  Thanks
  2021-06-09
  Reply
  Report
- Ehren:
  done reply back ty
  2021-06-09
  Reply
  Report
View more 1 comments
AnaiAnai
·2021-06-09
like
Reply
5
Report
Fold Replies
- AnaiAnai:
  ,,?
  2021-06-09
  Reply
  Report
- GiselleC:
  Pls comment baCk
  2021-06-09
  Reply
  Report
- GiselleC:
  Ok
  2021-06-09
  Reply
  Report
View more 1 comments
Ehren
·2021-06-09
like and comment ty
Reply
2
Report
Fold Replies
- Ehren:
  ty
  2021-06-09
  Reply
  Report
- GiselleC:
  Ok
  2021-06-09
  Reply
  Report
- GiselleC:
  Ok
  2021-06-09
  Reply
  Report
hyhop
·2021-06-09
Ok
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1166056944?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-08 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166056944","market":"us","top_or_hot":-1,"title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","media":"Motley Fool","content":"<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MGNI","symbol_name":"Magnite, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","article_id":"1166056944","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","pubTimestamp":1623160615,"sourceInfo":null,"weMediaInfo":null,"summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"translate_title":"华尔街的5只高辛烷值成长股，涨幅在54%至94%之间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MGNI":0.9,"PLUG":0.9,"TCNNF":0.9,"TDOC":0.9,"VXRT":0.9},"content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":163870789,"gmtCreate":1623878784241,"gmtModify":1703822124375,"author":{"id":"3585764169254376","authorId":"3585764169254376","name":"Shan_2021","avatar":"https://static.tigerbbs.com/8683f374343f61d0fbbf7acdfbca2bcc","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3585764169254376","authorIdStr":"3585764169254376"},"htmlText":"Not sure &nbsp;time will tell","listText":"Not sure &nbsp;time will tell","text":"Not sure time will tell","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/163870789","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":184191797,"gmtCreate":1623687343919,"gmtModify":1704208809577,"author":{"id":"3580639857080060","authorId":"3580639857080060","name":"zactan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3580639857080060","authorIdStr":"3580639857080060"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184191797","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":183685779,"gmtCreate":1623328693991,"gmtModify":1704200975970,"author":{"id":"3574137361000320","authorId":"3574137361000320","name":"Jac_jk","avatar":"https://static.tigerbbs.com/9ffa694dd3ac0cd86c872ef9e38bd3c9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3574137361000320","authorIdStr":"3574137361000320"},"htmlText":"Plug power financial report better be good&nbsp;","listText":"Plug power financial report better be good&nbsp;","text":"Plug power financial report better be good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/183685779","repostId":1166056944,"repostType":2,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4687624,"gmtCreate":1623414687990,"gmtModify":1663228469865,"authorId":3584317203205053,"author":{"id":3584317203205053,"idStr":"3584317203205053","authorId":3584317203205053,"name":"王尧SICS5","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183685779,"type":1,"supId":4681291,"prevId":0,"content":"Yep! ","text":"Yep! ","html":"Yep! "},{"id":4684949,"gmtCreate":1623406579338,"gmtModify":1663228456728,"authorId":3574137361000320,"author":{"id":3574137361000320,"idStr":"3574137361000320","authorId":3574137361000320,"name":"Jac_jk","avatar":"https://static.tigerbbs.com/9ffa694dd3ac0cd86c872ef9e38bd3c9","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183685779,"type":1,"supId":4681291,"prevId":0,"content":"Oh dear, another delayed ?","text":"Oh dear, another delayed ?","html":"Oh dear, another delayed ?"},{"id":4681291,"gmtCreate":1623394077311,"gmtModify":1663228440653,"authorId":3584317203205053,"author":{"id":3584317203205053,"idStr":"3584317203205053","authorId":3584317203205053,"name":"王尧SICS5","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":183685779,"type":1,"supId":0,"prevId":0,"content":"It defered 3 times!","text":"It defered 3 times!","html":"It defered 3 times!"}],"langContent":"EN"},{"id":180563104,"gmtCreate":1623212946208,"gmtModify":1704198490323,"author":{"id":"3581767141779758","authorId":"3581767141779758","name":"Monching","avatar":"https://static.tigerbbs.com/815eb9eaaae7adc0b9e3fefbb34eea00","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3581767141779758","authorIdStr":"3581767141779758"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180563104","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180242165,"gmtCreate":1623208757057,"gmtModify":1704198401803,"author":{"id":"3582764273979695","authorId":"3582764273979695","name":"WCS1981","avatar":"https://static.tigerbbs.com/f98e28d5b1695429dd1657ecc78f93f5","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582764273979695","authorIdStr":"3582764273979695"},"htmlText":"Missed buying teladoc at $130[LOL]&nbsp;","listText":"Missed buying teladoc at $130[LOL]&nbsp;","text":"Missed buying teladoc at $130[LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180242165","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180262482,"gmtCreate":1623206842246,"gmtModify":1704198360044,"author":{"id":"3554804006357295","authorId":"3554804006357295","name":"iamateh","avatar":"https://static.tigerbbs.com/cfa6492594e288f70d24f72146aeec45","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3554804006357295","authorIdStr":"3554804006357295"},"htmlText":"pls like and comment. thanks!!&nbsp;","listText":"pls like and comment. thanks!!&nbsp;","text":"pls like and comment. thanks!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180262482","repostId":1166056944,"repostType":2,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180877542,"gmtCreate":1623200262186,"gmtModify":1704198139596,"author":{"id":"3576813955258325","authorId":"3576813955258325","name":"A68","avatar":"https://static.tigerbbs.com/d209afa981c29a4dc34bd7c1c986fb4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576813955258325","authorIdStr":"3576813955258325"},"htmlText":"[Happy]&nbsp;","listText":"[Happy]&nbsp;","text":"[Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180877542","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180170929,"gmtCreate":1623196570061,"gmtModify":1704197989582,"author":{"id":"3568154809054444","authorId":"3568154809054444","name":"HappyCloud","avatar":"https://static.tigerbbs.com/39dc69f5461d4fc413d626e66aa91a90","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3568154809054444","authorIdStr":"3568154809054444"},"htmlText":"Pls like and comment. Thanks","listText":"Pls like and comment. Thanks","text":"Pls like and comment. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180170929","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":180131837,"gmtCreate":1623194112629,"gmtModify":1704197898471,"author":{"id":"3582668988155006","authorId":"3582668988155006","name":"MengKeng","avatar":"https://static.tigerbbs.com/daf999525f61ba41d3c13b0ed728eb77","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582668988155006","authorIdStr":"3582668988155006"},"htmlText":"Vaxart is interesting as it is developing a pill instead of injection for Covid-19.&nbsp; Hope it can be released so that shares will rise","listText":"Vaxart is interesting as it is developing a pill instead of injection for Covid-19.&nbsp; Hope it can be released so that shares will rise","text":"Vaxart is interesting as it is developing a pill instead of injection for Covid-19. Hope it can be released so that shares will rise","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/180131837","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4655385,"gmtCreate":1623278836055,"gmtModify":1663228311534,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3581734044994294,"repliedAuthor":{"id":3581734044994294,"idStr":"3581734044994294","authorId":3581734044994294,"name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":180131837,"type":1,"supId":4639097,"prevId":4639169,"content":"respond","text":"respond","html":"respond"},{"id":4655380,"gmtCreate":1623278825797,"gmtModify":1663228308936,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3581504334066898,"repliedAuthor":{"id":3581504334066898,"idStr":"3581504334066898","authorId":3581504334066898,"name":"JeffTai","avatar":"https://static.tigerbbs.com/eaf357935d6e8ef3744f3d94312f0a64","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":180131837,"type":1,"supId":4639097,"prevId":4639192,"content":"thanks","text":"thanks","html":"thanks"},{"id":4639192,"gmtCreate":1623194415602,"gmtModify":1663228233038,"authorId":3581504334066898,"author":{"id":3581504334066898,"idStr":"3581504334066898","authorId":3581504334066898,"name":"JeffTai","avatar":"https://static.tigerbbs.com/eaf357935d6e8ef3744f3d94312f0a64","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3581734044994294,"repliedAuthor":{"id":3581734044994294,"idStr":"3581734044994294","authorId":3581734044994294,"name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":180131837,"type":1,"supId":4639097,"prevId":4639169,"content":"good","text":"good","html":"good"},{"id":4639169,"gmtCreate":1623194360037,"gmtModify":1663228232234,"authorId":3581734044994294,"author":{"id":3581734044994294,"idStr":"3581734044994294","authorId":3581734044994294,"name":"Bonghanhuei","avatar":"https://static.tigerbbs.com/c688d7ad40c511adab3aa29cdc4befc5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180131837,"type":1,"supId":4639097,"prevId":0,"content":"good","text":"good","html":"good"},{"id":4639097,"gmtCreate":1623194174077,"gmtModify":1663228230869,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180131837,"type":1,"supId":0,"prevId":0,"content":"respond please","text":"respond please","html":"respond please"}],"langContent":"EN"},{"id":180131032,"gmtCreate":1623194091626,"gmtModify":1704197898310,"author":{"id":"3575595901245834","authorId":"3575595901245834","name":"jun26","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575595901245834","authorIdStr":"3575595901245834"},"htmlText":"Like comment","listText":"Like comment","text":"Like comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":6,"repostSize":0,"link":"https://ttm.financial/post/180131032","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639083,"gmtCreate":1623194140827,"gmtModify":1663228233141,"authorId":3579053062900901,"author":{"id":3579053062900901,"idStr":"3579053062900901","authorId":3579053062900901,"name":"Kelvinphan","avatar":"https://static.tigerbbs.com/dd87884547b7d5f0157a229e9ea4e890","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180131032,"type":1,"supId":0,"prevId":0,"content":"Done... pls help response back","text":"Done... pls help response back","html":"Done... pls help response back"},{"id":4639103,"gmtCreate":1623194191555,"gmtModify":1663228232043,"authorId":3579053062900901,"author":{"id":3579053062900901,"idStr":"3579053062900901","authorId":3579053062900901,"name":"Kelvinphan","avatar":"https://static.tigerbbs.com/dd87884547b7d5f0157a229e9ea4e890","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180131032,"type":1,"supId":4639083,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":4639086,"gmtCreate":1623194151145,"gmtModify":1663228230864,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180131032,"type":1,"supId":4639083,"prevId":0,"content":"respond back","text":"respond back","html":"respond back"},{"id":4639074,"gmtCreate":1623194129311,"gmtModify":1635331736435,"authorId":3578967818815253,"author":{"id":3578967818815253,"idStr":"3578967818815253","authorId":3578967818815253,"name":"LHJarsenal","avatar":"https://static.tigerbbs.com/a0d7e1e2167d189c3611e1bcef48e104","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180131032,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"},{"id":4639107,"gmtCreate":1623194194514,"gmtModify":1635331733406,"authorId":3581723087274150,"author":{"id":3581723087274150,"idStr":"3581723087274150","authorId":3581723087274150,"name":"edwinong","avatar":"https://static.tigerbbs.com/d42f3dae28f8c1740e66011b66f51ccd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3582839637303229,"repliedAuthor":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":180131032,"type":1,"supId":4639083,"prevId":4639086,"content":"done","text":"done","html":"done"}],"langContent":"EN"},{"id":180139722,"gmtCreate":1623194047866,"gmtModify":1704197897179,"author":{"id":"3578967818815253","authorId":"3578967818815253","name":"LHJarsenal","avatar":"https://static.tigerbbs.com/a0d7e1e2167d189c3611e1bcef48e104","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578967818815253","authorIdStr":"3578967818815253"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/180139722","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639049,"gmtCreate":1623194059970,"gmtModify":1635331738997,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139722,"type":1,"supId":0,"prevId":0,"content":"respond","text":"respond","html":"respond"}],"langContent":"EN"},{"id":180139479,"gmtCreate":1623194045091,"gmtModify":1704197896532,"author":{"id":"3581558525974959","authorId":"3581558525974959","name":"mreddeham","avatar":"https://static.tigerbbs.com/a6fa672c579549dff0b2d3edced5788b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581558525974959","authorIdStr":"3581558525974959"},"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/180139479","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639059,"gmtCreate":1623194070702,"gmtModify":1635331738141,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139479,"type":1,"supId":0,"prevId":0,"content":"raspberry up please","text":"raspberry up please","html":"raspberry up please"}],"langContent":"EN"},{"id":180139115,"gmtCreate":1623194017437,"gmtModify":1704197895556,"author":{"id":"3576734182904550","authorId":"3576734182904550","name":"Jamessss","avatar":"https://static.tigerbbs.com/6c712eae8eccf0013cc7d0e594915c60","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3576734182904550","authorIdStr":"3576734182904550"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/180139115","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639035,"gmtCreate":1623194031309,"gmtModify":1663228230865,"authorId":3576141127250570,"author":{"id":3576141127250570,"idStr":"3576141127250570","authorId":3576141127250570,"name":"Permapurps","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139115,"type":1,"supId":0,"prevId":0,"content":"Like and comment please","text":"Like and comment please","html":"Like and comment please"},{"id":4639073,"gmtCreate":1623194129271,"gmtModify":1663228230865,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139115,"type":1,"supId":4639035,"prevId":0,"content":"respond please","text":"respond please","html":"respond please"}],"langContent":"EN"},{"id":180139306,"gmtCreate":1623194016705,"gmtModify":1704197895394,"author":{"id":"3575252907553393","authorId":"3575252907553393","name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575252907553393","authorIdStr":"3575252907553393"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/180139306","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639082,"gmtCreate":1623194138330,"gmtModify":1663228232430,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139306,"type":1,"supId":0,"prevId":0,"content":"respond please","text":"respond please","html":"respond please"},{"id":4639085,"gmtCreate":1623194150171,"gmtModify":1663228231237,"authorId":3575252907553393,"author":{"id":3575252907553393,"idStr":"3575252907553393","authorId":3575252907553393,"name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139306,"type":1,"supId":4639082,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":4639124,"gmtCreate":1623194245637,"gmtModify":1663228228555,"authorId":3582839637303229,"author":{"id":3582839637303229,"idStr":"3582839637303229","authorId":3582839637303229,"name":"vxf","avatar":"https://static.tigerbbs.com/b1ee9a28e0a19bf5b87d52e90dc87788","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":3575252907553393,"repliedAuthor":{"id":3575252907553393,"idStr":"3575252907553393","authorId":3575252907553393,"name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"objectId":180139306,"type":1,"supId":4639082,"prevId":4639085,"content":"thank","text":"thank","html":"thank"},{"id":4639068,"gmtCreate":1623194108160,"gmtModify":1635331737165,"authorId":3571093498557443,"author":{"id":3571093498557443,"idStr":"3571093498557443","authorId":3571093498557443,"name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139306,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4639071,"gmtCreate":1623194122199,"gmtModify":1635331736798,"authorId":3575252907553393,"author":{"id":3575252907553393,"idStr":"3575252907553393","authorId":3575252907553393,"name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139306,"type":1,"supId":4639068,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"EN"},{"id":180139907,"gmtCreate":1623194013809,"gmtModify":1704197895071,"author":{"id":"3578558472894517","authorId":"3578558472894517","name":"Kayabunz","avatar":"https://static.tigerbbs.com/f55b83d8dfc7c9f14a1d8b86e9727914","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578558472894517","authorIdStr":"3578558472894517"},"htmlText":"Like likeeeee","listText":"Like likeeeee","text":"Like likeeeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/180139907","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639037,"gmtCreate":1623194031442,"gmtModify":1663228229334,"authorId":3571093498557443,"author":{"id":3571093498557443,"idStr":"3571093498557443","authorId":3571093498557443,"name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139907,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":180139046,"gmtCreate":1623193996785,"gmtModify":1704197894908,"author":{"id":"3571093498557443","authorId":"3571093498557443","name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"hat":"https://static.tigerbbs.com/ae1f49570794979e009a5efdeb6f4789","crmLevel":6,"crmLevelSwitch":1,"idStr":"3571093498557443","authorIdStr":"3571093498557443"},"htmlText":"Pls like n comment","listText":"Pls like n comment","text":"Pls like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/180139046","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639031,"gmtCreate":1623194024703,"gmtModify":1663228232041,"authorId":3575252907553393,"author":{"id":3575252907553393,"idStr":"3575252907553393","authorId":3575252907553393,"name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180139046,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"EN"},{"id":180130981,"gmtCreate":1623193954743,"gmtModify":1704197893776,"author":{"id":"3579053062900901","authorId":"3579053062900901","name":"Kelvinphan","avatar":"https://static.tigerbbs.com/dd87884547b7d5f0157a229e9ea4e890","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579053062900901","authorIdStr":"3579053062900901"},"htmlText":"Like &amp; comment&nbsp;","listText":"Like &amp; comment&nbsp;","text":"Like & comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/180130981","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639050,"gmtCreate":1623194060309,"gmtModify":1663228231840,"authorId":3579053062900901,"author":{"id":3579053062900901,"idStr":"3579053062900901","authorId":3579053062900901,"name":"Kelvinphan","avatar":"https://static.tigerbbs.com/dd87884547b7d5f0157a229e9ea4e890","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130981,"type":1,"supId":4639013,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":4639055,"gmtCreate":1623194067114,"gmtModify":1663228230868,"authorId":3579053062900901,"author":{"id":3579053062900901,"idStr":"3579053062900901","authorId":3579053062900901,"name":"Kelvinphan","avatar":"https://static.tigerbbs.com/dd87884547b7d5f0157a229e9ea4e890","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130981,"type":1,"supId":4639009,"prevId":0,"content":"Thanks","text":"Thanks","html":"Thanks"},{"id":4639009,"gmtCreate":1623193977748,"gmtModify":1663228230867,"authorId":3564036689292828,"author":{"id":3564036689292828,"idStr":"3564036689292828","authorId":3564036689292828,"name":"Ehren","avatar":"https://static.tigerbbs.com/cd05fa865c0d896cd68ab47c88c34536","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130981,"type":1,"supId":0,"prevId":0,"content":"done reply back ty","text":"done reply back ty","html":"done reply back ty"},{"id":4639013,"gmtCreate":1623193986898,"gmtModify":1635331742402,"authorId":3571093498557443,"author":{"id":3571093498557443,"idStr":"3571093498557443","authorId":3571093498557443,"name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130981,"type":1,"supId":0,"prevId":0,"content":"Pls coMment back","text":"Pls coMment back","html":"Pls coMment back"}],"langContent":"EN"},{"id":180130059,"gmtCreate":1623193952071,"gmtModify":1704197893615,"author":{"id":"3583884958321017","authorId":"3583884958321017","name":"AnaiAnai","avatar":"https://static.tigerbbs.com/8b0d0d8e20a4082ac0bc6a98756546ec","vip":1,"crmLevel":1,"crmLevelSwitch":1,"idStr":"3583884958321017","authorIdStr":"3583884958321017"},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/180130059","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639021,"gmtCreate":1623194009239,"gmtModify":1663228232139,"authorId":3583884958321017,"author":{"id":3583884958321017,"idStr":"3583884958321017","authorId":3583884958321017,"name":"AnaiAnai","avatar":"https://static.tigerbbs.com/8b0d0d8e20a4082ac0bc6a98756546ec","vip":1,"crmLevel":1,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130059,"type":1,"supId":4639007,"prevId":0,"content":",,?","text":",,?","html":",,?"},{"id":4639007,"gmtCreate":1623193974050,"gmtModify":1663228231235,"authorId":3571093498557443,"author":{"id":3571093498557443,"idStr":"3571093498557443","authorId":3571093498557443,"name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130059,"type":1,"supId":0,"prevId":0,"content":"Pls comment baCk","text":"Pls comment baCk","html":"Pls comment baCk"},{"id":4639004,"gmtCreate":1623193963858,"gmtModify":1663228231142,"authorId":3571093498557443,"author":{"id":3571093498557443,"idStr":"3571093498557443","authorId":3571093498557443,"name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130059,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4639047,"gmtCreate":1623194056468,"gmtModify":1635331739242,"authorId":3564036689292828,"author":{"id":3564036689292828,"idStr":"3564036689292828","authorId":3564036689292828,"name":"Ehren","avatar":"https://static.tigerbbs.com/cd05fa865c0d896cd68ab47c88c34536","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180130059,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"EN"},{"id":180197251,"gmtCreate":1623193929673,"gmtModify":1704197892969,"author":{"id":"3564036689292828","authorId":"3564036689292828","name":"Ehren","avatar":"https://static.tigerbbs.com/cd05fa865c0d896cd68ab47c88c34536","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3564036689292828","authorIdStr":"3564036689292828"},"htmlText":"like and comment ty","listText":"like and comment ty","text":"like and comment ty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/180197251","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4639052,"gmtCreate":1623194065604,"gmtModify":1663228233043,"authorId":3564036689292828,"author":{"id":3564036689292828,"idStr":"3564036689292828","authorId":3564036689292828,"name":"Ehren","avatar":"https://static.tigerbbs.com/cd05fa865c0d896cd68ab47c88c34536","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180197251,"type":1,"supId":4638996,"prevId":0,"content":"ty","text":"ty","html":"ty"},{"id":4639061,"gmtCreate":1623194075250,"gmtModify":1663228231038,"authorId":3571093498557443,"author":{"id":3571093498557443,"idStr":"3571093498557443","authorId":3571093498557443,"name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180197251,"type":1,"supId":4638996,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4638996,"gmtCreate":1623193936878,"gmtModify":1635331744114,"authorId":3571093498557443,"author":{"id":3571093498557443,"idStr":"3571093498557443","authorId":3571093498557443,"name":"GiselleC","avatar":"https://static.tigerbbs.com/179da162ff2a45271bfe253a23405416","vip":1,"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":180197251,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":180197625,"gmtCreate":1623193929567,"gmtModify":1704197893454,"author":{"id":"3570089742250981","authorId":"3570089742250981","name":"hyhop","avatar":"https://static.tigerbbs.com/0c810c839e0549461f5f465b72f9be83","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3570089742250981","authorIdStr":"3570089742250981"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/180197625","repostId":1166056944,"repostType":4,"repost":{"id":"1166056944","pubTimestamp":1623160615,"share":"https://ttm.financial/m/news/1166056944?lang=&edition=fundamental","pubTime":"2021-06-08 21:56","market":"us","language":"en","title":"5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1166056944","media":"Motley Fool","summary":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns","content":"<blockquote>If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.</blockquote>For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health &amp; Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 21:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nIf analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader ...\n\n<a href=\"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MGNI":"Magnite, Inc.","TCNNF":"Trulieve Cannabis Corporation","TDOC":"Teladoc Health Inc.","VXRT":"Vaxart, Inc","PLUG":"普拉格能源"},"source_url":"https://www.fool.com/investing/2021/06/08/5-high-octane-growth-stocks-with-54-to-94-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1166056944","content_text":"If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year.For the past 12 years, growth stocks have been the key to sending the broader market higher. Even though value stocks have been the better performer of the two categories over the very long-term, historically low lending rates and trillions of dollars being pumped into the U.S. economy have created a perfect storm for growth stocks to thrive.Yet according to Wall Street's one-year consensus price targets, somegrowth stocksaren't anywhere near realizing their full potential. If analysts' consensus price targets prove accurate, the following five high-octane growth stocks offer upside ranging from 54% to 94% over the next year.Vaxart: Implied upside of 94%The supercharged growth stock on this list with thegreatest implied upsideover the coming 12 months is clinical-stagebiotech stockVaxart(NASDAQ:VXRT). If you're wondering why I've included a clinical-stage drug developer, it's because all of the analysts covering it are forecasting recurring sales for the company, beginning in 2022. If Wall Street's estimates are correct, Vaxart's stock could nearly double from where it closed this past week.What makes Vaxart such a unique drug developer is its approach to developing treatments. Specifically, it develops oral recombinant vaccines, rather than vaccines administered by injection. It should be a lot easier to dispense and administer pills than injections, which could resolve factors like shot hesitancy and vaccine access.Even though it has multiple treatments in the works, most of the buzz surrounding Vaxart has to do with its work in the lab on VXA-CoV2-1, an experimental oral tablet to treat the coronavirus disease 2019 (COVID-19). Data from a phase 1 study in February showed VXA-CoV2-1 met all of its primary and secondary safety and immunogenicity endpoints. The data also signaled that Vaxart's oral treatment may be effective against COVID-19 variants.Though it's probablya bit too earlyto get overly excited about Vaxart, it's a name worth closely monitoring.Trulieve Cannabis: Implied upside of 88%It's no secret that cannabis is set to be one of North America's fastest-growing industries this decade. But amongmarijuana stocks, U.S. multistate operator (MSO)Trulieve Cannabis(OTC:TCNNF)offers some of the most robust upside. If Wall Street's consensus price target of a little over $72 is correct, Trulieve could gallop higher by 88% over the coming year.There are a lot of unique growth strategies among MSOs, but none hasproved more successful than Trulieve's blueprint. At the moment, Trulieve has 88 operational dispensaries. But here's the kicker: 82 of them are located in medical marijuana-legal Florida. By focusing its efforts on a single big-dollar state, Trulieve has been able to saturate the market, effectively build up its brand, and keep its marketing costs down. The company has been profitable for 13 consecutive quarters, and as of the end of 2020 controlled 53% of the Sunshine State's dried flower market and 49% of its high-margin cannabinoid oils market.Equally intriguing is Trulieve's recently announced all-stock deal to acquire MSOHarvest Health & Recreation(OTC:HRVSF)for $2.1 billion. Harvest has a focus on five states, one of which happens to be Florida. Aside from solidifying an even bigger presence in the Sunshine State, Trulieve will gain access to Harvest's state-leading 15 dispensaries in Arizona. The Grand Canyon State legalized recreational weed in November. There's a good chance Trulieve can use Harvest's infrastructure to duplicate its success in Arizona.Magnite: Implied upside of 59%Another high-octane growth stock with significant upside potential, according to Wall Street, is sell-side advertising technology platformMagnite(NASDAQ:MGNI). If analysts are correct about Magnite hitting nearly $46 a share in 12 months, it would represent upside potential of 59%.Magnite finds itself at the center of a double-digit growth trend that should last for a long time to come. As consumers cut the cord to traditional cable and shift to other forms of entertainment and content consumption, businesseswill be more likely to shift their advertising dollarsonline, to apps, and to streaming/connected TV (CTV). Although mobile platforms accounted for almost half of Magnite's revenue last year, it's CTV that looks to be the most intriguing long-term growth driver.One of thebiggest boostsfor Magnite should come from its recently closed cash-and-stock acquisition of SpotX. SpotX generated $31.2 million in sales (less traffic acquisition costs) in the first quarter, with $19.7 million of this net revenue attributable to CTV. That was up 70% from the prior-year period. The now-combined company has sell-side ad platform exposure to the likes offuboTV,Roku,Disney, and WarnerMedia, to name a few leading platforms.With Magnite profitable on a recurring basis and fully capable of sustainable double-digit growth, a 59% 12-month return isn't out of the question.Teladoc Health: Implied upside of 56%Transformativehealthcare stockTeladoc Health(NYSE:TDOC)is also expected to offer abundant upside potential. Based on Wall Street's consensus price target of around $229, Teladoc could rise by a cool 56% over the next 12 months.A lot of folks view Teladoc asone of the biggest winners during the COVID-19 pandemic. With doctors wanting to keep high-risk people and infected patients out of their offices, many turned to virtual visits. Teladoc ultimately handled 10.59 million telehealth visits last year, up from 4.14 million in 2019. But these folks are probably overlooking that Teladoc grew sales by an annual average of 74% in the six years leading up to the pandemic.What makes telemedicine such a winning trend is that itoffers advantages up and down the treatment chain. Telehealth allows patients to stay home for consultations, and it's a tool physicians can use to keep closer tabs on their chronically ill patients. This ease of oversight could result in improved patient outcomes. It also doesn't hurt that virtual visits are billed at a lower rate than office visits.Following its acquisition of leading applied health signals company Livongo Health in the fourth quarter, Teladoc has all the tools needed to provide next-level personalized care. In other words, this price target looks very realistic over the next year.Plug Power: Implied upside of 54%Finally, hydrogen fuel-cell solutions companyPlug Power(NASDAQ:PLUG)is a (pardon the irony) high-octane growth stock with ample upside. If analysts are correct about its price target of almost $47 in a year, Plug could deliver a 54% return to its shareholders.The big buzz with Plug Power is the push by developed countries, including the U.S., to renewable sources of energy. President Biden has proposed a massive infrastructure bill tailored to renewable energy projects, which signals the federal government's willingness to invest in clean-energy solutions.Since the year began, Plug Power landed two major joint venture partners. South Korea's SK Group took a 10% equity stake in Plug and will work with the company to develop hydrogen fuel-cell solutions for vehicles and refilling stations. Meanwhile, French auto companyRenaultformed a joint venture with Plug to tackle Europe's light commercial vehicle market. Following these joint venture announcements, the companyintroduced a gross billings target of $1.7 billion by 2024, which would almost quadruple its forecasted sales for 2021.Whether it'll be smooth sailingremains to be seen. The company recently restated years' worth of its income statements, and history hasn't always been kind to the introduction of new automotive technology.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":285,"commentSize":217,"repostSize":0,"favoriteSize":4,"likeStatus":false,"favoriteStatus":false}}